371 related articles for article (PubMed ID: 27231341)
1. Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling.
Wang H; Lu B; Castillo J; Zhang Y; Yang Z; McAllister G; Lindeman A; Reece-Hoyes J; Tallarico J; Russ C; Hoffman G; Xu W; Schirle M; Cong F
J Biol Chem; 2016 Jul; 291(29):15256-66. PubMed ID: 27231341
[TBL] [Abstract][Full Text] [Related]
2. Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins.
Wang W; Li N; Li X; Tran MK; Han X; Chen J
Cell Rep; 2015 Oct; 13(3):524-532. PubMed ID: 26456820
[TBL] [Abstract][Full Text] [Related]
3. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
[TBL] [Abstract][Full Text] [Related]
4. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
[TBL] [Abstract][Full Text] [Related]
5. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
6. The RNF146 and tankyrase pathway maintains the junctional Crumbs complex through regulation of angiomotin.
Campbell CI; Samavarchi-Tehrani P; Barrios-Rodiles M; Datti A; Gingras AC; Wrana JL
J Cell Sci; 2016 Sep; 129(18):3396-411. PubMed ID: 27521426
[TBL] [Abstract][Full Text] [Related]
7. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.
Casás-Selves M; Kim J; Zhang Z; Helfrich BA; Gao D; Porter CC; Scarborough HA; Bunn PA; Chan DC; Tan AC; DeGregori J
Cancer Res; 2012 Aug; 72(16):4154-64. PubMed ID: 22738915
[TBL] [Abstract][Full Text] [Related]
8. Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations.
Troilo A; Benson EK; Esposito D; Garibsingh RA; Reddy EP; Mungamuri SK; Aaronson SA
Oncotarget; 2016 May; 7(20):28765-82. PubMed ID: 27144834
[TBL] [Abstract][Full Text] [Related]
9. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
[TBL] [Abstract][Full Text] [Related]
10. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14.
Huang JM; Nagatomo I; Suzuki E; Mizuno T; Kumagai T; Berezov A; Zhang H; Karlan B; Greene MI; Wang Q
Oncogene; 2013 Apr; 32(17):2220-9. PubMed ID: 22689061
[TBL] [Abstract][Full Text] [Related]
11. Angiomotins link F-actin architecture to Hippo pathway signaling.
Mana-Capelli S; Paramasivam M; Dutta S; McCollum D
Mol Biol Cell; 2014 May; 25(10):1676-85. PubMed ID: 24648494
[TBL] [Abstract][Full Text] [Related]
12. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
13. YAP promotes erlotinib resistance in human non-small cell lung cancer cells.
Hsu PC; You B; Yang YL; Zhang WQ; Wang YC; Xu Z; Dai Y; Liu S; Yang CT; Li H; Hu B; Jablons DM; You L
Oncotarget; 2016 Aug; 7(32):51922-51933. PubMed ID: 27409162
[TBL] [Abstract][Full Text] [Related]
14. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
15. Amot130 adapts atrophin-1 interacting protein 4 to inhibit yes-associated protein signaling and cell growth.
Adler JJ; Heller BL; Bringman LR; Ranahan WP; Cocklin RR; Goebl MG; Oh M; Lim HS; Ingham RJ; Wells CD
J Biol Chem; 2013 May; 288(21):15181-93. PubMed ID: 23564455
[TBL] [Abstract][Full Text] [Related]
16. Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade.
Jia J; Qiao Y; Pilo MG; Cigliano A; Liu X; Shao Z; Calvisi DF; Chen X
PLoS One; 2017; 12(9):e0184068. PubMed ID: 28877210
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for tankyrase-RNF146 interaction reveals noncanonical tankyrase-binding motifs.
DaRosa PA; Klevit RE; Xu W
Protein Sci; 2018 Jun; 27(6):1057-1067. PubMed ID: 29604130
[TBL] [Abstract][Full Text] [Related]
18. AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.
Scarborough HA; Helfrich BA; Casás-Selves M; Schuller AG; Grosskurth SE; Kim J; Tan AC; Chan DC; Zhang Z; Zaberezhnyy V; Bunn PA; DeGregori J
Clin Cancer Res; 2017 Mar; 23(6):1531-1541. PubMed ID: 27663586
[No Abstract] [Full Text] [Related]
19. RNF166 promotes colorectal cancer progression by recognizing and destabilizing poly-ADP-ribosylated angiomotins.
Li Y; Zhang X; Liu N; Liu R; Zhang W; Chen L; Chen Y
Cell Death Dis; 2024 Mar; 15(3):211. PubMed ID: 38480683
[TBL] [Abstract][Full Text] [Related]
20. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]